Author

D. H. Fuller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 9 Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:host-pathogen & immune response· 9 Organism:mouse· 5 Organism:non-human primate· 5 Assay:proteomics· 5 Research Focus:drug response / drug discovery· 4 Organism:rat· 4 Research Focus:cell type annotation· 3

Frequent Co-Authors

M. A. O'Connor· 6 shared D. W. Hawman· 5 shared A. C. Walls· 4 shared H. Feldmann· 4 shared J. Archer· 4 shared J. H. Erasmus· 4 shared S. Leventhal· 4 shared S. Randall· 4 shared

Activity by Year

2020-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

M. A. O'Connor

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals

A. A. Cohen, J. R. Keeffe, A. Schiepers, S. E. Dross, A. J. Greaney, A. V. Rorick, H. Gao, P. N. P. Gnanapragasam, C. Fan, A. P. West, A. I. Ramsingh, J. H. Erasmus, J. D. Pata, H. Muramatsu, N. Pardi, , P. J. Bjorkman

The paper shows mosaic-8b nanoparticles induce broader cross-reactive antibodies than homotypic ones, even in pre-vaccinated animals, suggesting potential for improved vaccine design against emerging sarbecoviruses.

bioRxiv · Feb 8, 2024Immunology

Protein design for evaluating vaccines against future viral variation

N. Youssef, S. Gurev, F. Ghantous, K. P. Brock, J. A. Jaimes, N. N. Thadani, A. Dauphin, A. C. Sherman, L. Yurkovetskiy, D. Soto, R. Estanboulieh, B. Kotzen, P. Notin, A. W. Kollasch, A. A. Cohen, , D. Marks

The paper designs SARS-CoV-2 Spike proteins with novel mutations to evaluate vaccine effectiveness against future viral variants using a deep learning model.

bioRxiv · Oct 8, 2023Immunology

A replicon RNA vaccine induces durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned

M. A. O'Connor, D. W. Hawman, K. Meade-White, S. Leventhal, W. Song, S. Randall, J. Archer, T. B. Lewis, B. Brown, N. Iwayama, C. Ahrens, W. Garrison, S. Wangari, K. A. Guerriero, P. Hanley, , J. H. Erasmus

This study shows a replicon RNA vaccine provides durable protection against SARS-CoV-2 in nonhuman primates even after neutralizing antibodies decline.

bioRxiv · Aug 8, 2022 · PreprintImmunology

Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice

A. C. Walls, L. A. VanBlargan, K. Wu, A. Choi, M. J. Navarro, D. Lee, L. Avena, D. M. Berrueta, M. N. Pham, S. Elbashir, M. C. Miranda, E. Kepl, M. Johnson, A. Blackstone, K. R. Sprouse, , D. Veesler

This study compares neutralizing antibody responses to SARS-CoV-2 variants in vaccinated humans and mice, finding that mice do not accurately reflect the breadth and potency seen in humans.

bioRxiv · Feb 7, 2022Immunology

Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine

D. W. Hawman, K. Meade-White, C. Clancy, J. Archer, T. Hinkley, S. Leventhal, D. Rao, A. Stamper, M. Lewis, R. Rosenke, K. Krieger, S. Randall, A. P. Khandhar, L. Hao, T.-Y. Hsiang, , J. Erasmus

bioRxiv · Jan 31, 2022Microbiology

SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern

D. W. Hawman, K. Meade-White, J. Archer, S. Leventhal, D. Wilson, C. Shaia, S. Randall, A. P. Khandhar, T.-Y. Hsiang, M. Gale, P. Berglund, D. H. Fuller, H. Feldmann, J. Erasmus

This study evaluates a replicating RNA vaccine against SARS-CoV-2 variants, showing protection from disease and reduced viral shedding after heterologous challenge.

bioRxiv · Dec 10, 2021Microbiology

Macaque-human differences in SARS-CoV-2 Spike antibody response elicited by vaccination or infection

A. Willcox, K. Sung, M. E. Garrett, J. G. Galloway, M. A. OConnor, J. H. Erasmus, J. K. Logue, D. W. Hawman, H. Y. Chu, K. J. Hasenkrug, D. H. Fuller, F. A. Matsen, J. Overbaugh

This study compares SARS-CoV-2 Spike antibody responses between macaques and humans after vaccination or infection, identifying shared and distinct epitope recognition patterns and escape pathways.

bioRxiv · Dec 1, 2021 · PreprintImmunology

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

A. C. Walls, M. C. Miranda, M. N. Pham, A. Schaefer, A. Greaney, P. S. Arunachalam, M.-J. Navarro, M. A. Tortorici, K. Rogers, M. A. O'Connor, L. Shireff, D. E. Ferrell, N. Brunette, E. Kepl, J. E. Bowen, , Veesler

This study shows that a SARS-CoV-2 RBD nanoparticle vaccine protects against SARS-CoV-2 and related sarbecoviruses, including variants, in mice and non-human primates.

bioRxiv · Mar 15, 2021Immunology

Rapid progression is associated with lymphoid follicle dysfunction in SIV-infected infant rhesus macaques

M. P. Wood, C. I. Jones, A. Lippy, B. G. Oliver, B. Walund, K. A. Fancher, B. S. Fisher, P. J. Wright, J. T. Fuller, P. Murapa, J. Habib, M. Mavigner, A. Chahroudi, D. N. Sather, D. H. Fuller, D. Sodora

This study identifies lymphoid follicle dysfunction as a key factor in rapid disease progression in SIV-infected infant rhesus macaques.

bioRxiv · Dec 31, 2020Immunology

Protection from viral rebound after therapeutic vaccination with an adjuvanted DNA vaccine is associated with SIV-specific polyfunctional CD8 T cells in the blood and mesenteric lymph nodes

H. C. Tunggal, P. V. Munson, M. A. O'Connor, N. Hajari, S. E. Dross, D. Bratt, J. T. Fuller, K. Bagley, D. H. Fuller

This study shows that a therapeutic DNA vaccine with adjuvants protects some SIV-infected macaques from viral rebound by enhancing polyfunctional CD8 T cells in blood and gut lymph nodes.

bioRxiv · Sep 16, 2020 · PreprintMicrobiology

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2

A. C. Walls, B. Fiala, A. Schaefer, S. Wrenn, M. N. Pham, M. Murphy, L. V. Tse, L. Shehata, M. A. O'Connor, C. Chen, M. J. Navarro, M. C. Miranda, D. Pettie, R. Ravichandran, J. C. Kraft, , N. P. King

This study designs SARS-CoV-2 nanoparticle vaccines that induce strong neutralizing antibodies in mice, with higher titers and lower doses than existing trimer vaccines.

bioRxiv · Aug 11, 2020Immunology

Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates

J. H. Erasmus, A. P. Khandhar, A. C. Walls, E. A. Hemann, M. A. O'Connor, P. Murapa, J. Archer, S. Leventhal, J. Fuller, T. Lewis, K. E. Draves, S. Randall, K. A. Guerriero, M. S. Duthie, D. Carter, , D. H. Fuller

bioRxiv · May 28, 2020 · PreprintImmunology